SavedAdd your journal

Journals / Güncel Retina Dergisi / 2019 / Cilt: 3 - Sayı: 1

Aflibercept Treatment and Regimes in Macular Edema Secondary to Central Retinal Vein Occlusion

Santral Retinal Ven Tıkanıklığına Sekonder Makula Ödeminde Aflibercept Tedavisi ve Tedavi Rejimleri

Zeynep ALKIN
Gökhan DEMİR
Pages
31–34
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review will briefly cover the treatment options and discuss in greater detail the efficacy and safety of aflibercept.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Central retinal vein occlusion (CRVO) is the most common vascular disease leading cause of vision loss after diabetic retinopaty(DR) and branch retinal vein occlusion (BRVO).
📊
Key Findings & Data:The pathogenesis of CRVO involves a thrombus formation leading to increased retinal capillary pressure, increased vascular permeability, and possibly retinal neovascularization.
💡
Conclusion & Impact:This review will briefly cover the treatment options and discuss in greater detail the efficacy and safety of aflibercept.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Central retinal vein occlusion (CRVO) is the most common vascular disease leading cause of vision loss after diabetic retinopaty(DR) and branch retinal vein occlusion (BRVO). The pathogenesis of CRVO involves a thrombus formation leading to increased retinal capillary pressure, increased vascular permeability, and possibly retinal neovascularization. Vision loss due to CRVO is commonly caused by macular edema. Multiple treatment modalities have been used to treat macular edema. Currently, the most common therapy modality used is intravitreal inhibition of vascular endothelial growth factor (VEGF). The three most widely used agents are aflibercept, bevacizumab, and ranibizumab. In addition, intraocular steroids can be used to treat macular edema. This review will briefly cover the treatment options and discuss in greater detail the efficacy and safety of aflibercept.

Özet

Santral retinal ven tıkanıklığı(SRVT), diabetik retinopati (DRP) ve retina ven dal tıkanıklığından(RVDT) sonra görme azalmasına sebep olan en sık görülen vasküler hastalıktır. SRVT’nin patogenezi, kapiller basınç artışı, vasküler geçirgenlik artışı ve muhtemel retinal neovaskülarizasyona sebep olan trombüs oluşumudur. SRVT’de görme kaybının en sık sebebi makula ödemidir (MÖ). Makula ödeminin tedavisinde kullanılan birçok tedavi modalitesi vardır. Şimdilik, intravitreal vasküler endotelyal büyüme faktörü inhibitörleri (anti-VEBF) en sık kullanılan tedavi yöntemidir. Aflibercept, bevacizumab ve ranibizumab en sık kullanılan ajanlardır. Bunun yanısıra, intravitreal steroidler de MÖ tedavisinde kullanılabilir. Bu derleme, tedavi seçeneklerini kısaca ele alacak ve afliberceptin etkinliğini ve güvenliğini daha ayrıntılı olarak tartışacaktır.

🔖

Cite This Article

ALKIN, Z., DEMİR, G. (2019). Aflibercept Treatment and Regimes in Macular Edema Secondary to Central Retinal Vein Occlusion. Güncel Retina Dergisi, Cilt: 3 - Sayı: 1, 31–34. https://ajindex.com/articles/161139

References (13)

  1. Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, et al. Natural history of branch retinal vein occlusion: An evidence‑based systematic review. Ophthalmology 2010;117(6):1094‑101
  2. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: Pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117(2):313-9
  3. Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: Review of the literature. Eye (Lond) 2011;25(8):981-8
  4. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996;114(10):1243-7
  5. Kolar P. Risk factors for central and branch retinal vein occlusion: A meta- analysis of published clinical data. J Ophthalmol 2014;2014:724780
  6. Mitry D, Bunce C, Charteris D. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal veinocclusion. Cochrane Database Syst Rev 2013;(1):CD009510
  7. Braithwaite T, Nanji AA, Lindsley K, Greenberg PB. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 2014;(5):CD007325
  8. Clarkson JG, Chuang E, Gass D, Pedroso M, Cubillas T, Duria ES, et al. Baseline and early natural history report. The Central Vein Occlusion Study. Arch Ophthalmol. 1993;111(8):1087–1095
  9. Clarkson JG, Chuang E, Gass D, Pedroso M, Cubillas T, Duria ES et al. The Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. Ophthalmology. 1995;102(10):1434–1444
  10. Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology 2011;118(1):119- 133 11. Hayreh SS, Zimmerman MB. Ocular neovascularization associated with central and hemicentral retinal vein occlusion. Retina. 2012;32(8):1553–1565
  11. Christoffersen NL, Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology. 1999;106(11):2054–2062
  12. Clarkson JG, Chuang E, Gass D, Pedroso M, Cubillas T, Duria ES et al. The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology. 1995;102(10):1425–1433
  13. Hikichi T, Konno S, Trempe CL. Role of the vitreous in central retinal vein occlusion. Ret